NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion

CompletedN/A

Sponsor: iOMEDICO AG

Conditions: NTRK Family Gene Mutation

Countries: Germany, Switzerland

The objective of this registry is to analyze treatment reality and outcome of patients with locally advanced or metastatic solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Locally advanced or metastatic solid tumor with a documented NTRK gene fusion, based on a validated assay (according to current ESMO recommendations), or the provision of tumor material for central retesting
* Molecular pathology or molecular diagnostics report with details on NTRK gene fusion testing must be available
* Aged ≥ 18 years
* Signed and dated informed consent form (ICF) (only if patient is alive at time of data entry into the project; not applicable for inclusion of deceased patients' data)

Exclusion Criteria:

* Treatment with a TRK inhibitor prior to Sept 19th, 2019 (Germany) or May 28th, 2020 (Switzerland)
* Participation in a clinical trial with a TRK inhibitor before or at enrolment (liv-ing patients) or before inclusion (deceased patients)
* Deceased patients who have explicitly contradicted further use of data

Locations (26)

Augsburg, Germany
Berlin, Germany
Bremen, Germany
Cologne, Germany
Frankfurt, Germany
Freiburg im Breisgau, Germany
Hamburg, Germany
Hanover, Germany
Hanover, Germany
Heilbronn, Germany
Kempten, Germany
Landsberg, Germany
Lübeck, Germany
Mönchengladbach, Germany
München, Germany
Münster, Germany
Neuss, Germany
Ravensburg, Germany
Recklinghausen, Germany
Rosenheim, Germany
Schorndorf, Germany
Soest, Germany
Ulm, Germany
Villingen-Schwenningen, Germany
Wiesbaden, Germany
Basel, Switzerland